Clinical and Economic Consequences of Failure of Initial Antibiotic Therapy for Patients with Community-Onset Complicated Intra-Abdominal Infections

Objectives Complicated intra-abdominal infection (cIAI) is infection that extends beyond the hollow viscus of origin into the peritoneal space, and is associated with either abscess formation or peritonitis. There are few studies that have assessed the actual costs and outcomes associated with failure of initial antibiotic therapy for cIAI. The aims of this study were to evaluate risk factors and impact on costs and outcomes of failure of initial antibiotic therapy for community-onset cIAI. Methods A retrospective study was performed at eleven tertiary-care hospitals. Hospitalized adults with community-onset cIAI who underwent an appropriate source control procedure between August 2008 and September 2011 were included. Failure of initial antibiotic therapy was defined as a change of antibiotics due to a lack of improvement of the clinical symptoms and signs associated with cIAI in the first week. Results A total of 514 patients hospitalized for community-onset cIAI were included in the analysis. The mean age of the patients was 53.3 ± 17.6 years, 72 patients (14%) had health care-associated infection, and 48 (9%) experienced failure of initial antibiotic therapy. Failure of initial antibiotic therapy was associated with increased costs and morbidity. After adjustment for covariates, patients with unsuccessful initial therapy received an additional 2.9 days of parenteral antibiotic therapy, were hospitalized for an additional 5.3 days, and incurred $3,287 in additional inpatient charges. Independent risk factors for failure of initial antibiotic therapy were health care-associated infection, solid cancer, and APACHE II ≥13. Conclusions To improve outcomes and costs in patients with community-onset cIAI, rapid assessment of health care-associated risk factors and severity of disease, selection of an appropriate antibiotic regimen accordingly, and early infection source control should be performed.

[1]  P. Hsueh,et al.  Changing bacteriology of abdominal and surgical sepsis , 2012, Current opinion in infectious diseases.

[2]  J. D. De Waele,et al.  Essentials for Selecting Antimicrobial Therapy for Intra-Abdominal Infections , 2012, Drugs.

[3]  S. Blot,et al.  Critical Issues in the Clinical Management of Complicated Intra-Abdominal Infections , 2012, Drugs.

[4]  T. Babinchak,et al.  A multicentre, open-label, randomized comparative study of tigecycline versus ceftriaxone sodium plus metronidazole for the treatment of hospitalized subjects with complicated intra-abdominal infections. , 2010, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[5]  E. P. Dellinger,et al.  Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  H. Dupont,et al.  Clinical and microbiological profiles of community-acquired and nosocomial intra-abdominal infections: results of the French prospective, observational EBIIA study. , 2009, The Journal of antimicrobial chemotherapy.

[7]  G. Oster,et al.  Economic consequences of failure of initial antibiotic therapy in hospitalized adults with complicated intra-abdominal infections. , 2008, Surgical infections.

[8]  J. Mazuski Antimicrobial treatment for intra-abdominal infections , 2007, Expert opinion on pharmacotherapy.

[9]  Roberta B Carey,et al.  Invasive methicillin-resistant Staphylococcus aureus infections in the United States. , 2007, JAMA.

[10]  S. Sen,et al.  Consequences of inappropriate initial empiric parenteral antibiotic therapy among patients with community-acquired intra-abdominal infections in Spain , 2007, Scandinavian journal of infectious diseases.

[11]  E. Loh,et al.  The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[12]  Soumitra R. Eachempati,et al.  Longitudinal outcomes of intra-abdominal infection complicated by critical illness. , 2004, Surgical infections.

[13]  S. Sen,et al.  Effect of inappropriate initial empiric antibiotic therapy on outcome of patients with community-acquired intra-abdominal infections requiring surgery , 2004, European Journal of Clinical Microbiology and Infectious Diseases.

[14]  Claude D Martin,et al.  Clinical and therapeutic features of nonpostoperative nosocomial intra-abdominal infections. , 2004, Annals of surgery.

[15]  F. Fagnani,et al.  Cost of Care for Inpatients with Community-Acquired Intra-Abdominal Infections , 2002, European Journal of Clinical Microbiology and Infectious Diseases.

[16]  M. Silen,et al.  The impact of intraoperative culture on treatment and outcome in children with perforated appendicitis. , 1999, Journal of pediatric surgery.

[17]  S. Dougherty,et al.  Antimicrobial culture and susceptibility testing has little value for routine management of secondary bacterial peritonitis. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[18]  P. Barie,et al.  Surgical Infection Society intra-abdominal infection study. Prospective evaluation of management techniques and outcome. , 1993, Archives of surgery.

[19]  M. Schein Management of severe intra-abdominal infection. , 1992, Surgery annual.

[20]  I. Phillips,et al.  Microbiology of pyogenic liver abscess. , 1982, British medical journal.